To examine the importance of midline involvement and other clinicopathologic factors in predicting the rate of contralateral lymph node metastasis and survival in oral tongue squamous cell carcinoma.
I nvolvement of cervical lymphatics is thought to be the most important indicator of a poor outcome in squamous cell carcinoma (SCC) of the oral tongue. Nodal metastasis can decrease survival substantially. 1, 2 Patients with contralateral lymph node metastasis have a particularly poor prognosis. 1, 3 It is known that extension of the primary tumor to the midline increases the risk of contralateral lymph node metastasis 4, 5 and other clinicopathologic predictors have been examined with varying results. [5] [6] [7] [8] [9] The tendency for tumors that involve the midline to metastasize to the contralateral lymph nodes raises the question of a different survival in these patients. This would be useful to know especially when there is no clinical lymph node metastasis on presentation. This issue has not been addressed in the literature. Current surgical and radiotherapeutic guidelines for treatment of the contralateral neck lack the benefit of large studies that examine the factors predictive of contralateral lymph node metastasis and survival.
The objectives of this study are to use a population-based cancer registry to examine the effect of various clinicopathologic factors, including extension to the midline, T classification, grade, sex, race, and age, on the rate of contralateral lymph node metastasis for oral tongue SCC and to examine the effects of these factors on survival.
MATERIALS AND METHODS
We collected cases of oral tongue SCC from the Surveillance, Epidemiology, and End Results (SEER) program database from 1988 to 2004 for the following primary sites (site codes in parentheses): Dorsal surface of tongue not otherwise specified (NOS) (C02.0), Border of tongue (C02.1), Ventral surface of tongue (C02.2), and Anterior tow-third of tongue NOS (C02.3). SCC histologic subtypes included SCC NOS, keratinizing, large cell, small cell, spindle cell, microinvasive, clear cell type, papillary, and basaloid SCC, as well as Bowen disease and verrucous carcinoma.
We used SEER ''Extent of Disease'' codes to identify midline involvement for patients diagnosed between 1988 and 2002. For the oral tongue, SEER provides a value for the furthest extent of disease applicable to the case. The potential values are as follows: 10 = invasive tumor on 1 side confined to lamina propria or submucosa; 20 = musculature, intrinsic, or NOS; 30 = localized, NOS; 40 = tumor crosses midline; 50 = base of tongue, gingival, or floor of mouth; 60 = lateral pharyngeal wall or inferior surface of soft palate; 70 = mandible or maxilla; and 80 = extrinsic musculature. For years 2003 and 2004, SEER provides a ''Collaborative Staging Extension'' code that functions similarly and has similar values. One exception is that a ''midline tumor'' is coded as having less extension than a tumor that crosses midline. These midline tumors are given the same extension code as tumors listed as localized, NOS and this is considered less extension than crossing the midline. As a result of this, for 2 of the 16 years of our study, a minority of midline-arising tumors may not be counted as midline crossing in our analyses. Tumors centered exactly on the midline are uncommon and an analysis of contralateral lymph node metastasis would be nonsensical for these tumors as they presumably do not arise from 1 side. In summary, we included all tumors that are assigned an extent of disease value of 40 as involving the midline and all tumors with lesser values as being lateral only. Tumors assigned an extent of disease value greater than 40 are not included in analyses assessing the prognostic significance of midline crossing, and because of this, we are only able to examine T1-3 tumors that did not extend beyond the oral tongue in these analyses as outlined below.
We excluded patients from the study if they had previous primaries of the head and neck (393 cases). We also excluded cases if the nodal status was unknown (822 cases) in all analyses. In our analysis of the predictors of contralateral lymph node metastasis, we excluded the abovementioned cases and those coded in such a way that the laterality of the nodes was not explicitly stated as unilateral or contralateral (75 cases). In our Cox proportional hazards model, we excluded the cases in the 2 abovementioned categories and those coded in such a way that the number of ipsilateral nodes was not explicitly stated (383 cases). All survival analyses included only those patients who were treated with primary cancerdirected surgery. The median follow-up was 5 years, 2 months.
All staging data includes the information available from imaging and/or pathology within 4 months of diagnosis or up to the time of the first primary tumor-directed surgery. We refer to the staging performed in this time period as the stage ''at presentation'' throughout this manuscript. Staging was assigned according to the Seventh Edition of the American Joint Committee on Cancer Staging System according to extent of disease and tumor size, extent of nodal involvement, and presence or absence of distant metastasis as given in SEER. We used the w 2 statistic for univariable analysis of categorical variables and binary logistic regression for multivariable analysis. Survival was analyzed with Kaplan-Meier curves and a Cox proportional hazards model. All statistics were calculated on SPSS version 16 (SPSS Inc, Chicago, IL).
RESULTS
Our final dataset consisted of 5430 cases of SCC of the oral tongue. The mean age at diagnosis was 61 years with a standard deviation of 14.9 years. About 3194 (58.8%) patients were male and 2236 (41.2%) were female. About 4584 (84.4%) patients were listed as White, 342 (6.3%) were listed as African-American, and 461 (8.5%) were listed as other races.
One hundred thirty-five (2.5% of all patients) had contralateral lymph node metastasis. This represented 14.6% of the 922 patients in the study with any lymph node involvement. Most patients listed as not having contralateral lymph node metastasis were staged clinically. T1 tumors as well as T2 and T3 tumors that did not cross the midline or extend beyond the oral tongue were very unlikely to present with contralateral lymph node metastasis with rates ranging from 0.7% to 0.9% (Table 1) . Conversely, T4 tumors and lateral T2 and T3 tumors that extended across the midline but not beyond the oral tongue had rates ranging from 8.3% to 13.0%. T2 and T3 tumors that crossed the midline were 10.6 and 18.0 times more likely to go to the contralateral lymph nodes than strictly lateral tumors, respectively. Anatomic position and grade were not as powerful in predicting the presence of contralateral nodes. Contralateral nodes were involved more frequently in dorsal surface tumors than in ventral surface tumors (3.2% vs. 2.2%) and more frequently in high-grade tumors than in low-grade tumors (3.6% vs. 2.7%). Neither of these differences was statistically significant. Furthermore, verrucous carcinoma and papillary SCC subtypes never metastasized across the midline and only 2 of 80 had ipsilateral nodal involvement.
Extension across the midline retained its significance in predicting contralateral lymph node metastasis while holding other factors constant in logistic regression. Tumors that extend across the midline were more likely to involve the contralateral nodes with an odds ratio of 9.61 (P<0.001). No other clinicopathologic factor was statistically significant except the number of nodes examined, which was included as a control for the extent of neck dissection performed. The other factors examined included grade, T classification, race, age, and sex. About 2433 cases were included in the analysis.
Patients with tumors that cross the midline had a significantly decreased survival ( Fig. 1 ). Crossing the midline decreased mean survival by more than one-half (9 y 0.6 mo and 4 y 1.0 mo, respectively). We separated patients by T classification and again examined the survival of patients whose tumors crossed the midline versus those whose tumors did not. This was carried out to test the hypothesis that the effect of crossing the midline on survival is confounded by tumor size. Mean survival was lower for tumors that crossed the midline for T1 and T3 tumors and there was not a statistically significant difference for T2 tumors, although the trend remained. There were significant differences in survival among nodal groups (Fig. 2) . Specifically, any nodal disease at presentation decreased survival compared with patients with no nodal metastasis. In addition, when a single ipsilateral node was detected, mean survival was longer than when contralateral node(s) were detected. The difference between 1 ipsilateral node and multiple ipsilateral nodes, and the difference between multiple ipsilateral nodes and contralateral node(s) were not statistically significant.
When the analysis of the effect of crossing the midline on survival was broken down into nodal involvement groups, this survival advantage remained especially pronounced for patients who were node negative at presentation (8 y 9.9 mo and 4 y 9.3 mo, respectively). For patients with a single or multiple ipsilateral nodes or patients with contralateral nodes, there was no difference in mean survival. The survival for patients with contralateral lymph node metastasis on presentation was similar to the survival of N0 patients with tumors that crossed the midline.
While controlling for other clinicopathologic factors in a Cox proportional hazards model, tumors that cross the midline had statistically significant decreased survival with a hazard ratio of 2.18 ( Table 2 ). Other factors that conferred decreased survival were positive ipsilateral or contralateral nodes, T2 stage, male sex, older age, and highgrade tumors. Lymph node dissection as defined by pathologic examination of 4 or more nodes was associated with increased survival. As determined by the site-specific cause of death recode data in SEER, patients who died were almost 3 times more likely to die from oral tongue cancer when the tumor crossed the midline (36.2% vs. 12.4%, P value <0.001 by Pearson w 2 test). The cause of death was also more likely to be attributed to the tongue in node-positive patients, in patients with increasing T classification, in high-grade tumors, and in female patients as determined by univariable analysis.
DISCUSSION
The importance of midline involvement on survival raises the question of whether contralateral lymph node metastasis is being identified and/or treated aggressively enough. In the case of the ipsilateral neck, prophylacitic treatment generally improves locoregional control but the hypothesis that it improves survival has not been shown consistently in published analyses. [10] [11] [12] [13] [14] In patients with tongue SCC that does not cross the midline, it has been suggested that contralateral neck dissections are ineffective. In a study of stage I and II oral cavity SCC, Lim and colleagues 15 found only 1 case of occult contralateral lymph node metastasis in 25 elective contralateral neck dissections (4%). Patients were followed for a mean of 56.3 months and no cases of contralateral neck relapse were found. There was no survival benefit for contralateral prophylactic lymph node dissections. All patients had unilateral lesions that did not extend across the midline. In light of the results of this study, the rate may be much higher in patients with tumors that involve the midline. In another retrospective review of oral cavity carcinomas, Koo and colleagues 16 found that prophylactic contralateral neck dissection was more likely to reveal occult nodes when there was ipsilateral nodal involvement, or when the primary tumor crossed the midline. Five of 8 patients (63%) had occult contralateral lymph node metastasis in midline crossing primaries and only 1 of 20 (5%) had occult contralateral lymph node metastasis in nonmidline crossing primaries.
Prophylactic external beam radiation therapy of the contralateral N0 neck has been shown to decrease the rate of contralateral neck relapse for oral tongue SCC in some studies. [17] [18] [19] Northrop and others 19 reported that it occurred in only 1 of 22 (4.5%) patients treated with elective contralateral neck dissection and irradiation or irradiation only compared with 8 of 30 (26.7%) patients treated with radical neck dissection only in cases of oral tongue (N1-2a) SCC. Doses from 3000 cGy in 3 weeks to 5000 cGy in 5 weeks were given to the subdigastric area of the contralateral neck.
In our study, patients with T1 tumors and those with T2 or T3 tumors that did not cross the midline had rates of contralateral lymph node metastasis ranging from 0.7% to 0.9%. Given these results and those cited above, it is probably safe to withhold contralateral neck dissection for these patients when there is no clinical evidence of cervical metastasis at presentation. However, close observation is advised and longitudinal data is needed to determine the rate of subsequent conversion in the contralateral neck. Many studies have found that recurrence in the contralateral lymph nodes occurs largely within 2 years of diagnosis 7, 20, 21 and close surveillance is thus mandatory during this time period.
On account of limitations in SEER data, we were unable to tell which patients had clinically negative contralateral necks but were found to have contralateral disease at surgical neck dissection. The data are clear, however, that midline involvement remains the biggest factor predicting contralateral lymph node metastasis independent of T classification while controlling for the number of nodes sampled. The patients whose management stands to change the most from these findings are those with T2 disease with lesions extending to the midline and who are clinically N0, because at many centers these patients would not be offered contralateral neck dissection or radiation therapy. On account of the association we have shown between midline involvement and with contralateral lymph node metastasis, and perhaps more importantly, the significantly decreased overall survival, these patients may merit more aggressive treatment. Further prospective studies need to be undertaken to determine the benefit of prophylactic neck dissection and/or radiation therapy in these patients.
Among the few studies that have examined the clinicopathologic risk factors for contralateral lymph node metastasis, results have been inconsistent. Kowalski and colleagues 5 also found a higher risk for T4 tumors but there was no statistical relationship on multivariable analysis. Our study revealed an increased risk for T4 tumors on univariable analysis. In our multivariable analysis, we excluded cases in which the tumor extended beyond the oral tongue, that is, T4 tumors, so T4 classification may still be important. In a small series by Gonzalez-Garcia et al, 7 histopathologic grading and peritumoral inflammation were the only factors that were associated with contralateral lymph node relapse in the 9 patients in whom it occurred.
We found an incidence of contralateral lymph node metastasis of 2.5% at presentation (135 of 5430 patients). This is slightly below the rate found in other studies, which ranges from 3.0% to 9.2%. 5, 6, 9, 22, 23 In contrast to this study, many of these studies included only patients who received a contralateral neck dissection. The data in our analysis likely includes many cases in which postoperative radiation therapy to the neck is planned and for this reason providers have foregone a neck dissection that would have likely revealed positive nodes.
Lymphatic metastasis from the tongue can follow different patterns depending on the location of the primary tumor. It has been shown by Feind and Cole 6 that more anterior tumors are at a higher risk for contralateral neck involvement. In this study, there was an increased rate in patients with dorsal tongue tumors compared with ventral tongue tumors. The explanation for this may be similar to that of the anterior tongue effect in that metastases must travel longer through the tongue, and longer through the lymphatics, giving rise to more chance of crossover. Contralateral lymph node metastasis can only occur if the tumor involves or crosses the midline either clinically or subclinically or if the tumor comes close enough to the midline for small lymphatic structures that themselves cross the midline in the tongue are used. Lymphatic capillaries and collecting trunks that cross the midline exist and are used more frequently by centrally located primary tumors. 6 Vascular and perineural infiltration are 2 subclinical factors that may provide an anatomically rational explanation for increased contralateral neck involvement. 5 However, the propensity for vascular and neural structures to aid in spread across the midline can be expected to rise the closer the tumor is to the midline.
In SEER data, when contralateral metastasis is found, no information is given on the presence or extent of ipsilateral metastasis. Therefore, we were unable to examine the effect of ipsilateral lymph node metastasis on contralateral lymph node metastasis. This association has been shown in several studies [4] [5] [6] 8, 9 and this has led to the general practice of radiotherapeutic treatment of the contralateral neck when the ipsilateral neck is node positive. 15 We also did not include tumors arising directly on the midline because of the difficulty of assigning laterality to metastases.
CONCLUSIONS
For SCC of the oral tongue, contralateral lymph node metastasis is rarely found at presentation in T1 tumors and T2-3 tumors that do not extend across the midline. Special attention must be paid to the contralateral neck for patients with T2 or T3 tumors that cross the midline and for all T4 tumors. T classification is not a significant predictor of contralateral lymph node metastasis in tumors that do not extend beyond the oral tongue whereas primary midline involvement is extremely important. Contralateral lymph node metastasis is extremely unlikely for lateral verrucous or papillary SCC subtypes. When the oral tongue SCC crosses the midline, it portends significantly decreased survival, particularly in clinically N0 patients. Midline involvement is thus important in predicting the pattern of nodal spread and providing prognostic information about survival. A prospective, randomized trial would be more suitable to determine whether a survival advantage exists for elective treatment of the contralateral neck with surgical neck dissection and/or radiation therapy in these patients.
